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Immunotherapy improves immune homeostasis and in-
creases survival rate of septic patients
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Objective:    To investigate the efficacy of immunotherapy
on septic patients with Ulinastatin plus Thymosin-α1.
Methods:    Seventy postoperative septic patients were
divided into two groups at random: the immunotherapy
group (n=36) and the conventional therapy group (n=34).
Patients in the immunotherapy group received intravenous
Ulinastatin of 200 000 U, 3 times per day for 3 days,
Ulinastatin of 100 000 U, 3 times per day for 4 days, and
subcutaneous injection of Thymosin-α1 of 1.6 mg, twice
per day for 3 days, then once per day for 4 days. While
conventional therapies such as antibiotics and fluid resus-
citation were undertaken in both groups. The expression
levels of serum tumor necrosis factor-α (TNF-α),
interleukin-10 (IL-10), IgG, C3, T lymphocyte subsets, CD14
+
monocyte human leukocyte antigen (locus) DR (HLA-DR)
and patients’ 28-day survival rate of the two groups were
observed and evaluated.
Results:    The survival rate was significantly higher in
the immunotherapy group (63.9%; 23/36) compared with the
conventional therapy group (41.2%; 14/34). The serum TNF-α
levels [(1.38±0.50) ng/ml in the immunotherapy group vs
(1.88±0.53) ng/ml in the conventional group, P<0.05] and
the serum IL-10 levels [(217.52±15.71) ng/ml vs (101.53±16.57)
ng/ml, P<0.05] were significantly different between the two
groups. The serum IgG  levels in the immunotherapy group
[(17.65±6.81) g/L] were significantly higher than in the con-
ventional group [(11.94±5.32) g/L]. There were also signifi-
cant differences in the expression levels of CD4
+ T lym-
phocyte (35%±13% in the immunotherapy group vs
21%±7% in the conventional group, P<0.05) and CD14
+
monocyte HLA-DR (50%±5% in the former vs 35%±4% in
the latter, P<0.05).
Conclusions:    Immunotherapy with Ulinastatin plus
Thymosin-α1 can enhance the inflammatory response, im-
prove the immune homeostasis, and increase the survival
rate of septic patients.
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Sepsis is defined as a systemic inflammatoryresponse to infections.1 Immunological hostreactions are primarily believed to determine
the clinical course of this disease. An overwhelming
inflammatory response to microbial invasion may be
involved in the pathogenesis of systemic inflammatory
response syndrome (SIRS), sepsis and multiple organ
failure (MOF).2 The prevailing theory shows that sepsis
represents an uncontrolled inflammatory response.
Lewis Thomas3 has ever written “The microorganisms
seem to have it in for us. It turns out to be rather more
like bystanders. Our arsenals for fighting off bacteria
are so powerful that we are more in danger from them
than the invaders.” Thus, it is very important to block
the inflammatory response and alleviate sepsis injuries.
Immunotherapy is regarded as an effective approach to
improve the immunological function. Although bacteria
play a leading role in sepsis, the direct causes of death
for patients with sepsis are immune paralysis and in-
flammatory responses rather than the bacteria. In this
study, we used immunotherapy medications (Ulinastatin
and Thymosin-α1) to observe their effects on septic
patients and to study the functional mechanism.
METHODS
Selection of patients
The diagnosis of sepsis was made in accordance
with the criteria of the Consensus Conference Commit-
tee of the American College of Chest Physicians and
the Society of Critical Care Medicine.4 Six hours prior
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to initiation of treatment with medications, sepsis was
defined as SIRS with a documented infection (i.e. a
positive culture result). SIRS was diagnosed when two
or more of the following criteria were satisfied:
temperature>38°C or<36°C; heart rate>90 beats/min;
respiratory rate>20 breaths/min; white blood cell count>
12 000 cells/mm3 and <4 000 cells/mm3,  or immature
cells>10%. Patients were not eligible if they met any of
the following criteria: age<18 years or>80 years; incur-
able malignancies with documented metastases; long-
term treatment with high-dose immunosuppressive
drugs or receiving high-dose non-steroidal anti-inflam-
matory drugs within the previous 2 days; acute myo-
cardial infarction; chronic compensated organ dysfunc-
tion such as dialysis-dependent renal failure; moderate
to severe chronic heart failure. Patients in this study
came from the Hepatobiliary Surgery Department (64%),
the Gastrointestinal Surgery Department (19%), the Vas-
cular Surgery Department (9%), and other departments
(8%).
Evaluation of patients
In the original trial, patients were followed up for 28
days after the first day of treatment or until death. Pa-
tients’ histories were recorded and physical examina-
tions were performed. Vital signs were documented,
hematologic and biochemical tests were carried out,
lymphocyte subsets were enumerated, and levels of
cytokine and CD14
+ monocyte HLA-DR were measured
separately on 0, 1st, 3rd and 7th days after admission.
Laboratory values and organ-specific parameters were
used to calculate the acute physiology and chronic
health evaluation (APACHE) II scores5 and MOF
scores6.
Treatment methods
This prospective, randomized and placebo controlled
clinical study consisted of treatment and follow-up. Be-
fore the patients were recruited into this study, ethical
approval for the study was obtained from the local Re-
search Ethics Committee and informed consents for
participation were obtained from all the patients (either
from the patients themselves or from their relatives if
they were not able to give informed consents due to
severe sepsis) prior to the performance of any study-
related procedures. The patients were enrolled and re-
ceived treatment in the intensive care unit (ICU) after
they were diagnosed with sepsis. They received ran-
domly either antibiotics combining with Ulinastatin and
Thymosin-α1 (the immunotherapy group) or antibiotic
or the placebo (5% dextroglucose and water for
injection, the conventional therapy group). Randomiza-
tion was performed by picking a sealed envelope, with
the admission and start of treatment occurring on the
same day. Patients in the immunotherapy group re-
ceived an intravenous dose of Ulinastatin of 200 000 U,
3 times per day for 3 days, a subcutaneous dose of
Thymosin-α1 of 1.6 mg, twice per day for 3 days, fol-
lowed by a dose of 100 000 U Ulinastatin for 3 times
per day plus 1.6 mg Thymosin-α1 for once per day for
4 days successively. Patients in the conventional
therapy group received placebo in the same way. In
addition, standard ICU protocols were followed, includ-
ing empirical therapy for probable infection with Gram-
positive pathogens, maintenance of blood glucose con-
centrations between 8 and 10 mmol/L, resuscitation
and hemodynamic support, organ support, sedation or
analgesia as needed, and adequate nutrition.7, 8 In the
present study, weaning from support therapy was per-
formed in accordance with a weaning protocol.9 The
appropriate time for patients to leave the ICU was based
on physical examinations, laboratory results and or-
gan-specific parameters.
Medical resources
Synthetic Ulinastatin (Techpool, Guandong, China,
Batch No. 03060408) and Thymosin-α1 (Diao, Chendu,
China, Batch No. P006DH20050339) were prepared.
Flow cytometry (FCM) was used to count lymphocyte
subsets and CD14
+ monocyte HLA-DR. Cytokine levels
were determined by radioimmunoassay. The detection
limits of tumor necrosis factor (TNF)-αand IL-10 were
0.3, 0.9, 2.7, 8.1, and 24.3 ng/ml, respectively.
Statistical analysis
The primary analysis was based on the cumulative
survival rates of the randomized patients. All numeric
data were presented as mean±standard deviation.
Student’s t test was used to compare lymphocyte sub-
sets of the two groups at different time points. Chi-
square test was used to compare rates between the
two groups. P value <0.05 was considered significant.
Kaplan-Meier test was used for the 28-day survival rate
analysis. Statistical analyses were made using SPSS
software (Version 10.0).
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RESULTS
Clinical data of patients
There were no significant differences between the
conventional therapy group and the immunotherapy group
in terms of age, sex and APACHE II scores (P>0.05,
Table 1).
(P<0.05) and serum IL-10 levels increased more sig-
nificantly in the immunotherapy group than in the con-
ventional therapy group (P<0.05, Tables 2 and 3).
Humoral immunity
Serum IgG levels had a significant higher increase
in the immunotherapy group than in the conventional
therapy group (P<0.05) and C3 levels had little differ-
ences between the two groups (P>0.05, Tables 4 and 5).
Cell immunity
CD4
+ T lymphocytes increased more significantly in
the immunotherapy group than in the conventional therapy
group (35%±13% vs 21%±7%, P<0.05, Table 6).
Table 1.Clinical data of patients
                                         n         Age           Sex         APACHEⅡ
                                               (years)  (male/female)    scores
Conventional therapy
Immunotherapy
34    53 ± 13         28/6         9.7 ± 3.9
36    55 ±18          30/6         9.6 ± 4.2
Groups
Table 3. Serum IL-10 levels of the two groups (ng/ml)
165.52 ± 39.41  157.39 ± 18.41 190.05 ± 66.47   101.53 ± 16.57
167.41 ± 67.46  181.53 ± 56.59 185.44 ± 66.04     17.52 ± 15.71#
                            Time after treatment (d)
          0                        1                        3                         7Groups
Conventional therapy
Immunotherapy
#P<0.05, compared with the conventional therapy group.
Table 2. Serum TNF-α levels of the two groups (ng/ml)
Conventional therapy
Immunotherapy
1.75 ± 0.61
1.11 ± 0.45*
2.44 ± 0.17
2.51 ± 0.58
2.17 ± 0.15
2.49 ± 0.59
1.88 ± 0.53
1.38 ± 0.50*
*P<0.05, compared with the conventional therapy group.
                               Time after  treatment (d)
            0                      1                        3                         7Groups
△ P<0.05, compared with the conventional therapy group.
24 ± 11   19 ± 8   1.6 ± 1.3  25 ± 12   18 ± 7   1.5 ± 1.2    27 ± 12   16 ± 7   1.6 ± 0.9    29 ± 12    19 ± 11   1.9 ± 1.3
27 ± 13   25 ± 11 1.3 ± 1.0   27 ± 13   24 ± 9   1.4 ± 0.9    29 ± 14   23 ± 9   1.5 ± 0.9    35 ± 13*  21 ± 7     1.9 ± 1.3
Table 6. T lymphocyte subsets of the two groups
Conventional therapy
Immunotherapy
Groups
    0 day after treatment
CD4 (%)  CD8 (%)  CD4/CD8
    1 day after treatment
CD4 (%)  CD8 (%)  CD4/CD8
  3 days  after treatment
CD4 (%)  CD8 (%)  CD4/CD8
  7 days  after treatment
CD4 (%)  CD8 (%)  CD4/CD8
*P<0.05, compared with the conventional therapy group.
Cytokine levels
Serum TNF-α levels decreased more significantly
Conventional therapy
Immunotherapy
Table 4. IgG levels of the two groups (g/L)
   10.15 ± 3.51       9.53 ± 1.36      11.94 ± 5.32        15.54 ± 6.40
   10.39 ± 6.65       9.96 ± 3.60      17.65 ± 6.81△     14.55 ± 5.02
                             Time after treatment (d)
          0                        1                        3                         7Groups
                               Time after treatment (d)
          0                        1                        3                         7Groups
Conventional therapy
Immunotherapy
Table 5. C3 levels of the two groups (g/L)
     0.89 ± 0.34     0.84 ± 0.31      0.87 ± 0.41          0.83 ± 0.22
     0.66 ± 0.32     0.66 ± 0.14      0.83 ± 0.50          0.82 ± 0.56
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Lymphocyte counting and CD14
+ monocyte HLA-DR
had a more significant increase in the immunotherapy
group than in the conventional therapy group (50%±5%
vs 35%±4%, P<0.05, Fig.1).
The average survival time in the immunotherapy group
was 342 days (95%CI: 250-434 days) and that of the
conventional therapy group was 245 days (95%CI: 147-
343 days).
DISCUSSION
In the United States, the mortality rate of sepsis is
higher than any other major disease.10 Severe sepsis
is a common but difficult problem. Exciting advances
in the understanding of its pathophysiology11-13 and treat-
ment14 have been achieved recently.
The initial response to bacterial invaders is to re-
lease a variety of cytokines (e.g. TNF-α, IL-6 and IL-8),
which induce the synthesis of phospholipase A2, cyclo-
oxygenase,5-lipoxygenase and acetyltransferase. The
latter contributes to the synthesis of eicosanoids
(prostaglandins and leukotrienes) and platelet-activat-
ing factors, which promote inflammation and increase
blood flow and vascular permeability.15 Anti-inflamma-
tory cytokines (e.g. IL-10 and IL-12) down-regulate
proinflammatory cytokines. This effect is especially
important with respect to IL-10.16 Thus, this study ob-
served the levels of TNF-α, IL-8 and IL-10.
Mainstays for the treatment of sepsis include con-
trolling the source of infection, antimicrobial therapy,
resuscitation and hemodynamic support, organ support,
sedation or analgesia as needed and adequate nutrition.8
Monoclonal antibodies targeting lipopolysaccharide
were proved ineffective.17, 18 Using a single drug to change
inflammatory mediators (e.g. TNF-α, IL-1, platelet- ac-
tivating factor) has also been shown to be an ineffective
strategy.19 Therefore, our study used Ulinastatin and
Thymosin α1 as immunotherapy medications.
The lymphocyte subsets and inflammatory media-
tor levels were evaluated in our study. In the immuno-
therapy group, the level of TNF-α was lower, the CD4
+
T lymphocytes population was greater,  and IL-10, CD14
+
monocyte HLA-DR expression and the IgG level were
higher. The 28-day survival rate of the immunotherapy
group (63.9%) was also higher than that of the conven-
tional therapy group (41.2%).
    Lin et al20 in 2007 found that the 28-day mortality
rate of patients with multiple organ dysfunction syn-
drome who were treated with Ulinastatin and Thymosin-α1
Survival rate of patients
The number of non-survival patients in the two groups
was 33, all caused by MOF, with 20 in the conventional
therapy group and 13 in the immunotherapy group). Four-
teen (41.2%) patients survived in the conventional therapy
group  and twenty-three (63.9%) patients survived in the
immunotherapy group(P<0.05,  Fig. 2).
Fig. 1. Lymphocytes and CD14+ monocyte HLA-DR of the two
groups.
Fig. 2. Septic patients’ survival curves of the two groups.
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decreased from 38.32% to 25.14% (P =0.0088). Zhang
et al21 in 2008 found that the 28-day survival rate of pa-
tients with sepsis due to carbapenem-resistant bacte-
ria who received treatment with Ulinastatin and Thy-
mosin-α1 was 17.8%, which was much greater than
that of the control group. In a severe sepsis study in
2009, septic patients treated with Ulinastatin and Thy-
mosin-α1 achieved a survival rate of 78%, whereas
those treated with placebos survived only 60%.22
Limitations
The immunotherapy described in this study is
promising. However, there are also some limitations. It
is not clear whether the beneficial effects observed in
the study are due to Ulinastatin or Thymosin-α1. In
addition, more than one antibiotic medication was used
besides the study-targeted medications. All the septic
patients were from the general surgical departments.
And medical patients were not involved in this study as
well. Furthermore, the number of patients in each group
was different and each group was relatively small,
therefore, a larger clinical trial should be conducted to
validate the conclusions of the present study.
Conclusion
Immunotherapy with Ulinastatin plus Thymosin-α1
can enhance inflammatory response, improve immune
homeostasis and increase survival rate of the septic
patients (Fig. 3). It shows that immunotherapy is one
of the successful strategies aside from survival sepsis
campaign’s guideline.
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